טוען...
CXCR4 antagonists suppress small cell lung cancer progression
Small cell lung cancer (SCLC) is an aggressive tumor with poor prognosis due to early metastatic spread and development of chemoresistance. Playing a key role in tumor-stroma interactions the CXCL12-CXCR4 axis may be involved in both processes and thus represent a promising therapeutic target in SCL...
שמור ב:
| הוצא לאור ב: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Impact Journals LLC
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5356728/ https://ncbi.nlm.nih.gov/pubmed/27835905 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13238 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|